Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1991 Feb;29(2):386–389. doi: 10.1128/jcm.29.2.386-389.1991

Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis.

D Cohen 1, M S Green 1, C Block 1, R Slepon 1, I Ofek 1
PMCID: PMC269772  PMID: 1706731

Abstract

A means for determining immune status against shigellosis would significantly improve the design and evaluation of interventional and other epidemiologic studies. Previous case-control studies have indicated the potential role of humoral antilipopolysaccharide antibodies. To test this proposition, 190 soldiers serving in a field unit were monitored prospectively for 2.5 months for shigellosis. Blood samples were taken at the beginning of the follow-up period and tested for serological evidence of prior exposure to Shigella sonnei and Shigella flexneri. The risk for acquiring S. sonnei shigellosis was 3.7 times higher for individuals lacking homologous antibodies (P less than 0.02). The risk for acquiring S. flexneri shigellosis was 2.4 times higher for individuals lacking antibodies, although a low attack rate for S. flexneri resulted in numbers too small to achieve statistical significance. While the importance of the serum antilipopolysaccharide antibodies in protection against the disease remains unclear, these findings demonstrate that they are strong markers of acquired immunity. Serological markers should be incorporated in epidemiologic studies of shigellosis and in the design and evaluation of future trials of potential anti-Shigella vaccines.

Full text

PDF
386

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamus G., Mulczyk M., Witkowska D., Romanowska E. Protection against keratoconjunctivitis shigellosa induced by immunization with outer membrane proteins of Shigella spp. Infect Immun. 1980 Nov;30(2):321–324. doi: 10.1128/iai.30.2.321-324.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  3. Cohen D., Block C., Green M. S., Lowell G., Ofek I. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J Clin Microbiol. 1989 Jan;27(1):162–167. doi: 10.1128/jcm.27.1.162-167.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen D., Green M. S., Block C., Rouach T., Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis. 1988 May;157(5):1068–1071. doi: 10.1093/infdis/157.5.1068. [DOI] [PubMed] [Google Scholar]
  5. Dinari G., Hale T. L., Austin S. W., Formal S. B. Local and systemic antibody responses to Shigella infection in rhesus monkeys. J Infect Dis. 1987 May;155(5):1065–1069. doi: 10.1093/infdis/155.5.1065. [DOI] [PubMed] [Google Scholar]
  6. DuPont H. L., Gangarosa E. J., Reller L. B., Woodward W. E., Armstrong R. W., Hammond J., Glaser K., Morris G. K. Shigellosis in custodial institutions. Am J Epidemiol. 1970 Sep;92(3):172–179. doi: 10.1093/oxfordjournals.aje.a121195. [DOI] [PubMed] [Google Scholar]
  7. DuPont H. L., Hornick R. B., Snyder M. J., Libonati J. P., Formal S. B., Gangarosa E. J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972 Jan;125(1):12–16. doi: 10.1093/infdis/125.1.12. [DOI] [PubMed] [Google Scholar]
  8. Formal S. B., Kent T. H., May H. C., Palmer A., Falkow S., LaBrec E. H. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol. 1966 Jul;92(1):17–22. doi: 10.1128/jb.92.1.17-22.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Formal S. B., Maenza R. M., Austin S., LaBrec E. H. Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med. 1967 Jun;125(2):347–349. doi: 10.3181/00379727-125-32087. [DOI] [PubMed] [Google Scholar]
  10. HIGGINS A. R., FLOYD T. M., KADER M. A. Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am J Trop Med Hyg. 1955 Mar;4(2):281–288. [PubMed] [Google Scholar]
  11. Jertborn M., Svennerholm A. M., Holmgren J. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol. 1986 Aug;24(2):203–209. doi: 10.1128/jcm.24.2.203-209.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Keren D. F., Kern S. E., Bauer D. H., Scott P. J., Porter P. Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol. 1982 Jan;128(1):475–479. [PubMed] [Google Scholar]
  13. Klimpel G. R., Niesel D. W., Klimpel K. D. Natural cytotoxic effector cell activity against Shigella flexneri-infected HeLa cells. J Immunol. 1986 Feb 1;136(3):1081–1086. [PubMed] [Google Scholar]
  14. La Brooy J. T., Davidson G. P., Sherman D. J., Rowley D. The antibody response to bacterial gastroenteritis in serum and secretions. Clin Exp Immunol. 1980 Aug;41(2):290–296. [PMC free article] [PubMed] [Google Scholar]
  15. Lee M. R., Ikari N. S., Branche W. C., Jr, Young V. M. Microtiter bacterial hemagglutination technique for detection of Shigella antibodies. J Bacteriol. 1966 Jan;91(1):463–463. doi: 10.1128/jb.91.1.463-.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lowell G. H., MacDermott R. P., Summers P. L., Reeder A. A., Bertovich M. J., Formal S. B. Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. J Immunol. 1980 Dec;125(6):2778–2784. [PubMed] [Google Scholar]
  17. Madonna G. S., Allen R. C. Shigella sonnei phase I and phase II: susceptibility to direct serum lysis and opsonic requirements necessary for stimulation of leukocyte redox metabolism and killing. Infect Immun. 1981 Apr;32(1):153–159. doi: 10.1128/iai.32.1.153-159.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mel D. M., Terzin A. L., Vuksić L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ. 1965;32(5):647–655. [PMC free article] [PubMed] [Google Scholar]
  19. Morgan D. R., DuPont H. L., Gonik B., Kohl S. Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species. Infect Immun. 1984 Oct;46(1):25–33. doi: 10.1128/iai.46.1.25-33.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Niesel D. W., Hess C. B., Cho Y. J., Klimpel K. D., Klimpel G. R. Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp. Infect Immun. 1986 Jun;52(3):828–833. doi: 10.1128/iai.52.3.828-833.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reed W. P., Albright E. L. Serum factors responsible for killing of Shigella. Immunology. 1974 Jan;26(1):205–215. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES